Table 3.
Pooled estimates in MSCs group and no MSCs group
| Pooled estimates | Pooling model | Number of studies, haplo-HSCT + MSCs/haplo-HSCT alone | haplo-HSCT + MSCs (95% CI) | haplo-HSCT alone (95% CI) | OR (95% CI) | p value |
|---|---|---|---|---|---|---|
| aGVHD | Fixed/random | 7/9 | 56.0% (48.6%, 63.5%) | 47.2% (29.0%, 65.4%) | 1.43 (0.91–2.25) | 0.123 |
| Grade II–IV aGVHD | Fixed/random | 8/20 | 29.8% (24.1%, 35.5%) | 30.6% (26.6%,34.6%) | 0.97 (0.70–1.32) | 0.889 |
| cGVHD | Fixed/random | 8/18 | 25.4% (19.8%, 31.0%) | 30.0% (23.3%,36.6%) | 0.79 (0.56–1.11) | 0.187 |
| 2-year OS | Fixed/fixed | 8/12 | 84.9% (80.4%, 89.3%) | 85.2% (81.6%,88.8%) | 0.98 (0.60–1.61) | 1.000 |
| Engraftment rate | Fixed/fixed | 8/17 | 98.9% (96.4%, 100.0%) | 98.6% (96.5%,99.8%) | 1.02 (0.66–1.54) | 1.000 |
| CMV infection rate | Random/random | 5/10 | 52.4% (31.6–73.1%) | 64.1% (52.9–75.2%) | 0.61 (0.40–1.92) | 0.018 |
Abbreviations: GVHD graft-versus-host disease, aGVHD acute GVHD, cGVHD chronic GVHD, MSCs mesenchymal stromal cells, haplo-HSCT haplo-identical hematopoietic stem cell transplantation, OR odds ratio, OS overall survival, CI confidence interval, CMV cytomegalovirus